Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 2)

March 3, 2021 updated by: ObsEva SA

A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 study investigating the efficacy and safety of OBE2109 alone and in combination with add-back therapy for the treatment of uterine fibroids.

Subjects will be randomized to one of 5 treatment groups in a 1:1:1:1:1 ratio.

Study Type

Interventional

Enrollment (Actual)

511

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Bulgaria
      • Gabrovo, Bulgaria
        • Site reference ID 265
      • Pleven, Bulgaria
        • Site reference ID 255
      • Plovdiv, Bulgaria
        • Site reference ID 258
      • Sliven, Bulgaria
        • Site reference ID 266
      • Smolyan, Bulgaria
        • Site reference ID 264
      • Sofia, Bulgaria
        • Site reference ID 251
      • Sofia, Bulgaria
        • Site reference ID 252
      • Sofia, Bulgaria
        • Site reference ID 254
      • Sofia, Bulgaria
        • Site reference ID 256
      • Sofia, Bulgaria
        • Site reference ID 257
      • Sofia, Bulgaria
        • Site reference ID 267
  • Czechia
      • Praha, Czechia
        • Site reference ID 281
      • Praha, Czechia
        • Site reference ID 286
      • Praha, Czechia
        • Site reference ID 287
      • Praha, Czechia
        • Site reference ID 288
      • Písek, Czechia
        • Site reference ID 283
      • Příbram, Czechia
        • Site reference ID 284
      • Tábor, Czechia
        • Site reference ID 289
      • Vsetín, Czechia
        • Site reference ID 282
      • České Budějovice, Czechia
        • Site reference ID 285
  • Hungary
      • Baja, Hungary
        • Site reference ID 315
      • Budapest, Hungary
        • Site reference ID 303
      • Budapest, Hungary
        • Site reference ID 307
      • Debrecen, Hungary
        • Site reference ID 301
      • Debrecen, Hungary
        • Site reference ID 308
      • Debrecen, Hungary
        • Site reference ID 313
      • Kecskemét, Hungary
        • Site reference ID 314
      • Kistarcsa, Hungary
        • SIte reference ID 304
      • Nyíregyháza, Hungary
        • Site reference ID 306
  • Latvia
      • Riga, Latvia
        • Site reference ID 451
      • Riga, Latvia
        • Site reference ID 452
      • Riga, Latvia
        • Site reference ID 454
  • Lithuania
      • Kaunas, Lithuania
        • Site reference ID 463
      • Vilnius, Lithuania
        • Site reference ID 460
      • Vilnius, Lithuania
        • Site reference ID 461
      • Vilnius, Lithuania
        • Site reference ID 464
  • Poland
      • Białystok, Poland
        • Site reference ID 502
      • Katowice, Poland
        • Site reference ID 504
      • Katowice, Poland
        • Site reference ID 509
      • Katowice, Poland
        • Site reference ID 513
      • Katowice, Poland
        • Site reference ID 514
      • Knurów, Poland
        • Site reference ID 501
      • Lublin, Poland
        • Site reference ID 506
      • Lublin, Poland
        • Site reference ID 508
      • Lublin, Poland
        • Site reference ID 511
      • Piaseczno, Poland
        • Site reference ID 519
      • Poznań, Poland
        • Site reference ID 518
      • Przemyśl, Poland
        • Site reference ID 505
      • Szczecin, Poland
        • Site reference ID 503
      • Warsaw, Poland
        • Site reference ID 507
      • Łódź, Poland
        • Site reference ID 510
      • Łódź, Poland
        • Site reference ID 517
      • Świdnik, Poland
        • Site reference ID 512
  • Romania
      • Braşov, Romania
        • Site reference ID 606
      • Bucuresti, Romania
        • Site reference ID 601
      • Bucuresti, Romania
        • Site reference ID 603
      • Bucuresti, Romania
        • Site reference ID 604
      • Târgu-Mureş, Romania
        • Site reference ID 605
  • Ukraine
      • Chernivtsi, Ukraine
        • Site reference ID 813
      • Ivano-Frankivs'k, Ukraine
        • Site reference ID 801
      • Kharkiv, Ukraine
        • Site reference ID 814
      • Kyiv, Ukraine
        • Site reference ID 802
      • Kyiv, Ukraine
        • Site reference ID 803
      • Kyiv, Ukraine
        • Site reference ID 805
      • Kyiv, Ukraine
        • Site reference ID 806
      • Kyiv, Ukraine
        • Site reference ID 807
      • L'viv, Ukraine
        • Site reference ID 804
      • Odesa, Ukraine
        • Site reference ID 811
      • Ternopil', Ukraine
        • Site reference ID 808
      • Vinnytsia, Ukraine
        • Site reference ID 817
      • Zaporizhzhya, Ukraine
        • Site reference ID 812
      • Zaporizhzhya, Ukraine
        • Site reference ID 815
      • Zaporizhzhya, Ukraine
        • Site reference ID 816
  • United States
    • California
      • Chino, California, United States, 91710
        • Site reference ID 905
      • Huntington Park, California, United States, 29572
        • Site reference ID 918
      • San Diego, California, United States, 92123
        • Site reference ID 902
    • Colorado
      • Denver, Colorado, United States, 80209
        • Site reference ID 903
    • Florida
      • Bradenton, Florida, United States, 34209
        • Site reference ID 913
      • Orlando, Florida, United States, 32806
        • Site reference ID 912
    • Georgia
      • Augusta, Georgia, United States, 30912
        • Site reference ID 915
    • Idaho
      • Nampa, Idaho, United States, 83687
        • Site reference ID 924
    • Louisiana
      • Covington, Louisiana, United States, 70433
        • Site reference ID 926
      • Metairie, Louisiana, United States, 70006
        • Site reference ID 927
      • Metairie, Louisiana, United States, 92123
        • Site reference ID 900
    • Michigan
      • Canton, Michigan, United States, 48187
        • Site reference ID 901
      • Detroit, Michigan, United States, 48201
        • Site reference ID 932
    • Missouri
      • Jefferson City, Missouri, United States, 65109
        • Site reference ID 916
    • New Mexico
      • Albuquerque, New Mexico, United States, 87102
        • Site reference ID 930
    • New York
      • West Seneca, New York, United States, 14224
        • Site reference ID 933
    • North Carolina
      • Hamlet, North Carolina, United States, 28345
        • Site reference ID 931
    • Ohio
      • Westerville, Ohio, United States, 43081
        • Site reference ID 914
    • Pennsylvania
      • Erie, Pennsylvania, United States, 16507
        • Site reference ID 928
    • South Carolina
      • West Columbia, South Carolina, United States, 37203
        • Site reference ID 919
    • Texas
      • Houston, Texas, United States, 77058
        • Site reference ID 907
    • Utah
      • Salt Lake City, Utah, United States, 84124
        • Site reference ID 911
    • Wisconsin
      • Madison, Wisconsin, United States, 53717
        • Site reference ID 917

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Key Inclusion Criteria:

  • Premenopausal woman at screening.
  • Body Mass Index ≥ 18 kg/m2.
  • Menstrual cycles ≥ 21 days and ≤ 40 days.
  • Presence of uterine fibroids.
  • Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method.

Key Exclusion Criteria:

  • The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.
  • History of uterus surgery that would interfere with the study.
  • The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided.
  • Undiagnosed abnormal uterine bleeding.
  • Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: OBE2109 dose 1 (100mg) + Placebo Add-back
Drug: OBE2109
OBE2109 100mg tablets for oral administration once daily
Drug: Placebo to match OBE2109
Placebo to match OBE2109 100mg tablets for oral administration once daily
Drug: Placebo to match Add-back
Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Experimental: OBE2109 dose 1 (100mg) + Add-back
Drug: OBE2109
OBE2109 100mg tablets for oral administration once daily
Drug: Placebo to match OBE2109
Placebo to match OBE2109 100mg tablets for oral administration once daily
Drug: Add-back
Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Experimental: OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back
Drug: OBE2109
OBE2109 100mg tablets for oral administration once daily
Drug: Placebo to match Add-back
Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Drug: Add-back
Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Experimental: OBE2109 dose 2 (200mg) + Add-back
Drug: OBE2109
OBE2109 100mg tablets for oral administration once daily
Drug: Add-back
Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Placebo Comparator: Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back
Drug: OBE2109
OBE2109 100mg tablets for oral administration once daily
Drug: Placebo to match OBE2109
Placebo to match OBE2109 100mg tablets for oral administration once daily
Drug: Placebo to match Add-back
Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Drug: Add-back
Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24
Time Frame: From baseline to Week 24
Assessed using the alkaline hematin method
From baseline to Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to reduced menstrual blood loss
Time Frame: Up to Week 52
Assessed using the alkaline hematin method
Up to Week 52
Amenorrhea
Time Frame: Up to Week 52
Assessed using the alkaline hematin method
Up to Week 52
Time to amenorrhea
Time Frame: Up to Week 52
Up to Week 52
Number of days of uterine bleeding for the last 28-day interval prior to Week 24
Time Frame: last 28-day interval prior to Week 24
Assessed using the alkaline hematin method
last 28-day interval prior to Week 24
Number of days of uterine bleeding for each 28-day interval
Time Frame: Up to Week 52
Assessed using the alkaline hematin method
Up to Week 52

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone Mineral Density (BMD)
Time Frame: From baseline up to Week 76
Assessed by dual-energy X-ray absorptiometry (DXA) scan
From baseline up to Week 76
Endometrial biopsy
Time Frame: From baseline up to Week 52
Assessed by histology
From baseline up to Week 52
Adverse events
Time Frame: Up to Week 76
Frequency and severity of Treatment-Emergent Adverse Events
Up to Week 76

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

ObsEva SA

Investigators

  • Study Director: ObsEva SA, Geneva

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 23, 2017

Primary Completion (Actual)

September 16, 2019

Study Completion (Actual)

October 4, 2020

Study Registration Dates

First Submitted

February 17, 2017

First Submitted That Met QC Criteria

February 28, 2017

First Posted (Actual)

March 6, 2017

Study Record Updates

Last Update Posted (Actual)

March 5, 2021

Last Update Submitted That Met QC Criteria

March 3, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 16-OBE2109-009

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Uterine Fibroids

Clinical Trials on OBE2109

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe